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The current systematic review with meta-analysis of randomized controlled trials (RCTs) was aimed to evaluate the
effects of metformin on reproductive outcomes in patients with polycystic ovary syndrome (PCOS) who receive
gonadotropins for ovulation induction. After systematic review of electronic databases and websites for registration
of RCTs, a total of 7 RCTs reporting data on 1023 cycles were included in the final analysis. Descriptive data showed
an overall low studies’ quality due to unclear sequence generation and allocation concealment, lack of blinding
procedure, incomplete outcome data and several biases and/or confounders. Data synthesis showed that metfor-
min improved live-birth (odds ratio [OR] = 1.94, 95% confidence interval [CI] 1.10 to 3.44; P = 0.020) and pregnancy
(OR = 2.25, 95% CI 1.50 to 3.38; P < 0.0001) rates, without significant heterogeneity across the studies (P = 0.230,
estimation of inconsistency = 30%; and P = 0.710, estimation of inconsistency = 0%, respectively, for live-birth and
pregnancy rates). A significant reduction of cancellation rate was observed after metformin administration
(OR = 0.41, 95% CI 0.24 to 0.72, P = 0.002) without significant heterogeneity across the studies (P = 0.500, estimation
of inconsistency = 0%). Metformin administration influenced or did not influence other secondary endpoints
assessed with a significant heterogeneity. In conclusion, metformin administration increases the live-birth and
pregnancy rate in PCOS patients who receive gonadotropins for ovulation induction. Further well designed, blinded,
placebo-controlled, and adequately powered RCTs are need to confirm that metanalytic results.
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Metformin, an insulin sensitizer widely used for treating
type-2 diabetes mellitus, is employed in patients with
polycystic ovary syndrome (PCOS) in light of the scien-
tific data showing the pivotal role of insulin resistance in
the pathogenesis of the syndrome, and of its beneficial
effects on metabolism and ovulatory function in PCOS
women [1].
Experimental and translational data seem to suggest
that metformin could influence the ovarian response to
gonadotropins. In fact, it improves not only the systemic* Correspondence: stefanopalomba@tin.it
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stated.insulin sensitivity and serum androgen levels in PCOS
patients [1,2] but also their ovarian morphology [3] and
environment [2] by improving the intra-ovarian hyper-
androgenism through local effect on ovarian steroido-
genesis [4] and the intra-ovarian insulin-resistance [2,3]
interfering with autocrine/paracrine insulin-related sig-
naling [5,6]. These actions on the peripheral tissues are
irrespective of systemic improvement in metabolism and
ovulatory function [2]. In addition, scientific data suggest
an improvement of the endometrial receptivity in PCOS
patients under metformin treatment [7,8].
Gonadotropin administration represents a widely ac-
cepted therapeutic option to induce ovulation in PCOS
patients with anovulatory infertility [9,10], despite its high
direct and indirect costs and its high risk of side effects.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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could induce a normalization of the abnormal ovarian
responsiveness to gonadotropins, which is characteristic
in PCOS patients, as well as lead to an improvement of
their endometrial receptivity with an overall beneficial
effect in terms of pregnancies and live births. Further-
more, a previous meta-analysis [11] published on 2006
demonstrated that data regarding metformin administra-
tion during gonadotropin ovulation induction were in-
conclusive. In fact, the inclusion of only two randomized
controlled trials (RCTs) with less than 50 subjects each
and the lack of studies aimed to assess the pregnancy
rates limited the power of the analysis to exclude a treat-
ment benefit [11].
The current study was aimed to clarify the effects of
metformin in infertile PCOS patients who receive go-
nadotropin for ovulation induction through a systematic
review with meta-analysis of available RCTs.
Methods
The protocol design followed the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines for reporting systematic reviews and meta-
analyses of RCTs [12].
Study selection
Criteria for inclusion and exclusion of studies were
established prior to the literature search.
Only RCTs characterized by symmetric interventions
between the two treatment arms, i.e., patients who re-
ceived the same protocol for ovulation induction with
gonadotropins and then randomized to metformin or to
placebo/no treatment, were included. Crossover studies
were also included, although only data from the pre-
crossover phase were considered for meta-analysis.
Studies were excluded if non-randomized; if any follow-
up data were either not available, not extractable, not doc-
umented, or if the authors did not respond; if data were
inconsistent or suspected duplicate (corresponding author
was contacted by email and asked for clarification, and, if
no clarification was obtained, data sets were considered
overlapping and only the wider ones were included); if
they included subjects who received gonadotropins for
in vitro fertilization (IVF) programs.
No limit was given for PCOS diagnosis, dose and
protocol of intervention proposed, type of gonadotropin
used, and/or stimulation protocol employed.
Search strategy
The bibliographic search for identification of articles, ab-
stracts, and study protocols was conducted monthly up
to October 2013, with no language restriction.
A combination of the following medical subject head-
ings or keywords was included: “controlled ovarianhyperstimulation”, “controlled ovarian stimulation”, “fer-
tility”, “gonadotrophins”, “gonadotropins”, “infertility”,
“insulin sensitisers”, “insulin-sensitising drugs”, “insulin
sensitizers”, “insulin-sensitizing drugs”, “live-birth”, “met-
formin”, “OHSS” “ovarian hyperstimulation syndrome”,
“ovulation induction”, “PCOS”, “polycystic ovarian disease”,
“polycystic ovary disease”, “polycystic ovary syndrome”,
“polycystic ovarian syndrome”, “pregnancy”, “randomised
controlled trials”, “randomized controlled trials”, “RCTs”,
“sterility”, “sub-fertility”.
The following data sources were electronically searched:
MEDLINE through PubMed (1966 to October 2013),
EMBASE (1966 to September 2013), CINAHL (1981 to
October 2013), Cochrane Library (1970 to October 2013),
Clinical Evidence, UpToDate, and DARE for relevant
studies. The Institute for Scientific Information (ISI), Web
of Science, Scopus, Google Scholar, and the websites for
the registration of controlled trials were also consulted for
relevant clinical trials up to October 2013.
The bibliographies of retrieved articles, books and ex-
pert opinion review articles were manually searched and
reviewed. No systematic attempt to search the grey lit-
erature, defined as information produced on all levels of
government, academics, and/or business and industry in
electronic and print formats not controlled by commer-
cial publishing (International Conferences on grey litera-
ture, New York 2004), was made.
First, the titles and abstracts were screened and poten-
tially relevant articles were identified and reviewed for
inclusion/exclusion criteria. Then, the protocols and re-
sults of the studies were examined according to specific
inclusion criteria. Lastly, only studies that met the inclu-
sion criteria were considered for the final analysis.
Two independent reviewers (A.F., S.P.) not blinded at
any point to the authors or sources of publication simul-
taneously reviewed the full manuscripts of all citations
that possibly matched the predefined selection criteria.
Final inclusion or exclusion decisions were made on
examination of the full manuscripts. Disagreements be-
tween the reviewers on inclusion were discussed and
solved by consensus or arbitration after consultation
with an independent third author (G.B.L.S.).
Data extraction
The primary endpoints were the live-birth rate, defined
as the number of deliveries that resulted in at least one
live born baby for initiated cycle, and the pregnancy rate,
defined as number of pregnancies per initiated cycles [13].
The secondary endpoints included the rates of miscar-
riages, multiple pregnancy, cancelled cycles for either
poor- or hyper-response, ovarian hyperstimulation syn-
drome (OHSS), the stimulation length, the gonadotropin
dose, and the serum estradiol (E2) levels at human chori-
onic gonadotropin (hCG) injection [13].
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odological and procedural characteristics of each study
as well as a wide range of variables, including demo-
graphic, hormonal and metabolic characteristics of the
study population, definition of PCOS, and treatments re-
ceived with particular regard for type, protocols, and
doses. These data were all extracted and tabulated.
The collaboration of all corresponding authors was re-
quested, whenever possible, to obtain data missing from
the papers included in the study, as well as unpublished
and preliminary data.
Quantitative data analysis and synthesis
Statistical analyses were performed according to the stat-
istical guidelines for review authors developed by The
Cochrane Collaboration and published in the Cochrane
Handbook for Systematic Reviews of Interventions [14].
All the statistical analyses were performed by using Re-
view Manager Version 5 [15], provided by the Cochrane
Menstrual Disorders and Subfertility Group.
The analysis of the treatment effect was performed ac-
cording to the intention-to-treat (ITT) principle consid-
ering dropouts and missing data as treatment failures. In
consideration of the potential effect of metformin in a
pretreatment phase on pregnancy and live-birth, when
possible, the analysis was also performed also according
to the per-protocol method, considering the results only
from the patients who really received the infertility treat-
ment (gonadotropins with and/or without metformin).
Odds ratio (OR), with 95% confidence interval, was
used as a valid way of describing an intervention effect for
each dichotomous outcome using the Mantel-Haenszel
method [16]. In particular, OR describes the multiplication
of the odds of the outcome that occur with use of the
intervention [16]. Continuous outcome differences be-
tween the two groups were presented as mean difference
(MD) with 95% confidence interval.
A fixed-effect model was initially employed in the ana-
lysis, unless a significant heterogeneity occurred; a ran-
dom effects model analysis was used in order to account
for the extra uncertainty due to heterogeneity.
Potential heterogeneity of the treatment effects of each
trial was examined by testing for interactions between
source trial and treatment effects and estimation of in-
consistency (I2) [14,17]. Specifically, I2 represents an es-
timate of the degree of inconsistency among studies; I2
scores from 0% to 40% might not be important; from
30% to 60% may represent moderate heterogeneity; from
50% to 90% may represent substantial heterogeneity; and
from 75% to 100% considerable heterogeneity [14].
A P value lower than 0.05 or 95% CI that did not
contain unity was considered statistically significant. A
statistical trend was arbitrarily established for P values
that ranged between 0.05 and 0.09.The number needed to treat (NNT) was calculated
only for outcomes which were statistically significantly
different between metformin and control/placebo groups,
i.e. the expected number of people who need to receive
the experimental (metformin) rather than the comparator
intervention (no metformin) for one additional person to
either incur or avoid an event in a given time frame.Results
Search data
Figure 1 shows the flow diagram of the study selection
according to the PRISMA statement [12].
No unpublished study or in-progress study protocol
was identified.
Seven studies [18-24] were included in the final analysis.Studies description
The included studies [18-24] reported data on an overall
population of 334 PCOS subjects (167 and 167 for met-
formin and control arm, respectively). A total of 1023
cycles were analyzed (438 and 585 cycles under metfor-
min and no metformin, respectively).
Study quality is detailed in Figure 2. An overall low
studies’ quality due to unclear sequence generation and
allocation concealment, lack of blinding procedure, in-
complete outcome data and several biases and/or con-
founders were observed.
Table 1 summarizes the main characteristics of the
RCTs included in the final analysis.
A wide variability was found across studies in the
characteristics of participants, interventions performed
and outcomes measured.
In 2 [23,24] and 3 [18,19,21] RCTs, the diagnosis of
PCOS was made according to the European Society of Hu-
man Reproduction and Embryology (ESHRE)/American
Society of Reproductive Medicine (ASRM) [25] or to the
National Institute of Health (NIH) [26] criteria, respect-
ively, whereas in 2 RCTs [20,22] non-standardized criteria
were used. In particular, PCOS was diagnosed by the pres-
ence of oligomenorrhea, clinical and biochemical signs of
hyperandrogenism, polycystic ovaries (PCO) and follicle
stimulating hormone (FSH)/luteinizing hormone (LH) level
higher than 2 in 1 RCT [20], whereas it was diagnosed
by the presence of oligomenorrhea (an interval of at
least 56 days between menses) or amenorrhea (an inter-
val of at least 6 months between menses) in the other
one RCT [22].
PCOS phenotype of the studied population was de-
fined in no RCT.
In 4 studies [18-20,24], clomiphene citrate (CC)-resist-
ance was a specific inclusion criterion, whereas 3 other
RCTs [21-23] included patients with CC-resistance or
CC-failure.
Figure 1 Flow diagram of the study selection.
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glucose tolerance. On the other hand, in 2 other RCTs
[21,22], the presence of insulin resistance, univocally de-
fined as a glucose-to-insulin ratio <4.5 mg/10-4, was a
specific inclusion criterion.Figure 2 Study quality assessment.In 5 RCTs, a chronic [21,22] or a traditional low-dose
step-up [18-20] protocol was used with a starting dose
of 75 IU [18-21] or 50 IU [22] of recombinant FSH
(rFSH) [19,20,22], human urinary FSH (huFSH) [18] or
highly purified FSH (hpFSH) [21]. In 1 study [24], an
Table 1 Characteristics of included studies
Participants Outcomes Notes
De Leo et al [18] Sample size: - N. of ampoules of huFSH. Crossover study.
20 subjects - Serum E2 levels. No data on live-births.
Exclusion: - Days of treatment. No blind design.
- Abnormal FSH and/or prolactin levels. - Cancelled cycles. No criteria for defining OHSS.
- Abnormal thyroid function. - Incidence of OHSS. No criteria for cycle cancellation.
- Congenital adrenal hyperplasia. - Pregnancy rate.
- Abnormal partner’s seminal parameters. - Side effects.
- Drug assumption 2 mths prior to the study.
Yarali et al [19] Sample size: - N. of ampoules of rFSH. Data of spontaneous ovulation during
the pre-treatment phase were excluded.
32 subjects - Serum E2 levels.
Exclusion: - Days of treatment. No criteria for defining OHSS.
- Any infertility factor other than PCOS
(by semen analysis, hysterosalpingography,
and/or laparoscopy).
- Cancelled cycles. No data on OHSS.
- Endocrinopathies. - Pregnancy rate. No data on live-births.
- Abnormal glucose tolerance, IGT or
type-2 DM.
- Endometrial thickness. Cycle was cancelled in presence of more
than 3 follicles ≥15 mm, or in absence of
ovarian response after 35 days of treatment.
- Use of medications known to alter insulin
secretion
or action.
- Side effects.
Tasdemir
et al [20]
Sample size: - rFSH IU. No blind design.
32 subjects - serum E2 levels. No criteria for cycle cancellation.
Exclusion: - N. dominant follicles. No criteria for defining OHSS.
- Age <20 > 34. - Days of treatment. No data on live-births.
- Congenital adrenal hyperplasia. - Endometrial thickness. Not specified n. of side effects.
- Hyperprolactinemia. - Cancelled cycles.
- Hypothyroidism. - Incidence of OHSS.
- Abnormal renal and liver tests. - Pregnancy rate.
- Use of drugs with possible effect on
endogenous sex hormones.
- Multiple pregnancies.
- Type 1-2 DM. - Side effects.
- Hypophysal insufficiency.
- Any infertility factor other than PCOS (by
semen analysis, hysterosalpingography,
and/or laparoscopy).
Palomba
et al [21]
Sample size: - N. of ampoules of hpFSH. Only insulin-resistant women were included.
70 subjects - Serum E2 levels. IUI was performed in ovulating women who
failed to conceive.
Exclusion: - N. dominant follicles. TI was performed in non-ovulating women.
- Age <20 or >34 years. - Days of treatment. Cycle was cancelled in presence of more than
3 follicles ≥14 mm, or in absence of ovarian
response after 35 days of treatment.- BMI >30 and <18 kg/m
2. - Cancelled cycles.
- Neoplastic, metabolic (including glucose
intolerance), hepatic, and cardiovascular
disorder or other concurrent medical illness.
- Incidence of OHSS.
- Hypothyroidism. - Ovulation rate.
- Hyperprolactinaemia. - Rate of mono-ovulatory
cycles.
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- Cushing’s syndrome; non-classical congenital
adrenal
- Pregnancy rate.
- hyperplasia. - Multiple pregnancy rate
(primary end-point).
- Abuse of alcohol. - Abortion.
- Current or previous (within 6 mths) use of oral
contraceptives, glucocorticoids, antiandrogens,
antidiabetic, and anti-obesity and hormonal
drugs.
- Live-birth rate.
- Organic pelvic diseases. - Side effects.
- Previous pelvic surgery.
- Suspected peritoneal factor infertility.
- Tubal or male factor infertility (by
hysterosalpingogram and semen analysis).
- Intention to start a diet or a specific program
of physical activity.
van Santbrink
et al [22]
Sample size: - Units of rFSH (primary
end-point).
Only insulin-resistant women were included.
20 subjects - Serum E2 levels. No clear definition for CC-resistance and
CC-failure.
Exclusion: - Days of treatment (primary
end-point).
- Age ≤18≥ 37 yrs - Cancelled cycles. No specific definition for PCOS.
- Abnormal serum E2 and FSH levels. - Incidence of OHSS. No criteria for defining OHSS.
- Abnormal serum prolactin and thyroxine levels. - Ovulation rate. No specification of the time of metformin
and placebo administration.
- DM. - Rate of mono-ovulatory
cycles.
- Signs of liver or kidney insufficiency and heart
or vascular disease.
- Pregnancy rate. The study was divided into two phases. Only
the 2nd phase was considered in the analysis.
- Multiple pregnancy rate.
- Abortion. No data on live-births.
- Serious side effects. Cycle was cancelled in presence of more than
3 follicles ≥15 mm, or in absence of ovarian
response at the maximum dosage
(225IU rFSH daily).
Cheng et al [23] Sample size: - N. of ampoules of HMG. No data on the days of treatment.
60 subjects - Serum E2 levels. No data of the multiple pregnancies.
Exclusion: - N. dominant follicles. No data on live-births.
- Age ≥ 40 yrs. - Cancelled cycles. No data on side effects.
- Endometrial pathology. - Incidence of OHSS. No criteria for defining OHSS.
- Abnormal glucose tolerance (75g OGTT). - Ovulation rate. Cycle was cancelled in presence of more than
4 dominant follicles.
- Any infertility factor other than PCOS. - Rate of mono-ovulatory
cycles.
- Other common causes of hyperandrogenism. - Pregnancy rate (primary
end-point).
- Prolactinoma.
- Congenital adrenal hyperplasia.
- Cushing syndrome.
- Virilizing ovarian or adrenal tumours.
- Hormonal drugs assumption 3 mths prior
to the study.
Begum
et al [24]
Sample size: - Ovulation rate. No blind design.
110 subjects - Miscarriage. No criteria for defining OHSS.
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Exclusion: - Perinatal outcome. No criteria for cycle cancellation due
to hyper-response.
-DM. - Pregnancy rate (primary
end-point).
- Altered glucose metabolism. - Live-birth rate (primary
end-point).
No clear strategy (TI or IUI).
- Hyperprolactinemia.
- Hypothyroidism.
- Endometriosis.
- Pelvic inflammatory disease.
- Tubal factor infertility.
- Partner abnormal semen parameters.
BMI: body mass index; CC: clomiphene citrate; DM: diabetes mellitus; E2: estradiol; GIR: glucose to insulin ratio; HMG: human menopausal gonadotropins; hpFSH:
human purified follicle-stimulating hormone; huFSH: human urinary FSH; IGT: impaired glucose tolerance; IUI: intrauterine insemination; LH: luteinizing hormone;
OGTT: oral glucose tolerance test; OHSS: ovarian hyper-stimulation syndrome; PCOS: polycystic ovary syndrome; rFSH: recombinant FSH; SHBG: sex-hormone bind-
ing globulin; TI: timed intercourse.
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75 IU rFSH. In another study [23] a fixed dose protocol
consisting in 50 mg daily of CC from days 3 to 5 of the
menstrual cycle plus human menopausal gonadotropins
(HMG) administrated from day 5 with a starting dose of
75 IU daily was used.
Metformin was administered as pretreatment in all
studies with the exception of 1 RCT [23] with a daily
dose of 1500 mg [18,23,24] or 1700 mg [19-22]. Pretreat-
ment duration was extremely variable, i.e., 4 [18,24], 6
[19], 8 [20], 12 [21], or 14 [22] weeks before gonado-
tropin administration. Metformin use continued until
ovulation triggering in 3 RCTs [18,19,22] or pregnancy
test in 4 RCTs [20,21,23,24], whereas in no case was
treatment continued during pregnancy.
The control group received gonadotropins plus pla-
cebo in 4 RCTs [19,21,22,24] or gonadotropins alone in
3 RCTs [18,20,24].
In all studies [18,24], ovarian maturation was triggered
by means of urinary hCG at the dosage of 10,000 IU
[18-21,24] or 5,000 IU [22,23], when at least 1 periovula-
tory follicle was detected [18,23].
Criteria initially adopted for cycle cancellation were
heterogeneous among RCTs [18-24]. In particular, cycle
was cancelled due to hyper-response in presence of
more than 3 [18,19,21,22], 4 [23], or 5 [20] periovulatory
follicles. No criteria for cycle cancellation due to hyper-
response was given by Begum et al. [24]. Criteria for
cycle cancellation due to hypo-response were not re-
ported in 3 RCTs [18,20,23]; instead, 3 RCTs [19,21,24]
reported their cycle cancellation criterion as being no
follicular response after 30 [24] or 35 [19,21] days of
stimulation and 1 RCT [22] in case of no follicular re-
sponse with a maximum dosage of 225IU rFSH daily. At
study end, in 5 RCTs [18,20-23] cycles were always can-
celled for excessive ovarian response, whereas in only 2RCTs [19,24] the cycles were cancelled for no ovarian
response.
Timed intercourses were performed in 5 RCTs
[18-20,22,23], except in 1 RCT [21], in which women
who previously failed to ovulate underwent timed inter-
course whereas women who ovulated in the previous
cycles but did not achieve a pregnancy underwent intra-
uterine insemination. In 1 study [24], the strategy used
was not specified.
Luteal phase support was administrated in only 1 RCT
[23]. It consisted in 20 mg/day progesterone cream given
topically for 14 days after ovulation triggering [23].Meta-analysis
ITT analysis
Figures 3, 4 and 5 show the primary and secondary end-
points analyzed according to the ITT principle.
Data on the live birth rate were available in 2 RCTs
[21,24]. Metformin increased significantly the live birth
rate (OR = 1.94, 95% CI 1.10 to 3.44, P = 0.020), without
significant heterogeneity across the studies (P = 0.230, I2 =
30%) (Figure 3A). Considering the live-birth as treatment-
related event, the NNT was of 14 benefits (95% CI 8.5 to
40.4 benefits).
Based on meta-analysis of all 7 included RCTs [18-24],
metformin significantly increased the pregnancy rate
(OR = 2.25, 95% CI 1.50 to 3.38, P < 0.001), without sig-
nificant heterogeneity across the studies (P = 0.710, I2 =
0%) (Figure 3B). Considering the pregnancy as treatment-
related event, the NNT was of 5.7 benefits (95% CI 2 to 9
benefits).
Data on the rate of multiple pregnancies were formally
reported in 3 RCTs [20,21,24]. After meta-analysis, no
effect on multiple pregnancy rate was observed under
metformin (OR = 0.32, 95% CI 0.08 to 1.23; P = 0.100),
Figure 3 Meta-analysis of primary endpoints performed using ITT principles. Live-birth (A) and pregnancy (B) rates.
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0.480, I2 = 0%) (Figure 4A).
Data on the miscarriage rate were available in 5 RCTs
[19,21-24]. After meta-analysis, no significant effect on
the miscarriage rate was observed under metformin
(OR = 0.47, 95% CI 0.14 to 1.54; P = 0.210), without sig-
nificant heterogeneity across the studies (P = 0.290,
I2 = 0%) (Figure 4B).
After meta-analysis of all included RCTs [18-24], a sig-
nificant reduction of the cancellation rate was observed
after metformin administration (OR = 0.41, 95% CI 0.24
to 0.72, P = 0.002), without significant heterogeneity across
the studies (P = 0.500, I2 = 0%) (Figure 4C). Considering
the reduction in cycle cancellation as treatment-related
event, the NNT was of 25.6 benefits (95% CI 12 to 32
benefits).
Data on the OHSS rate were available in 5 RCTs
[18,20-23]. After meta-analysis, no significant effect of
metformin on the OHSS rate (OR = 0.56, 95% CI 0.26 to
1.21; P = 0.140) was observed, without significant hetero-
geneity across the studies (P = 0.610, I2 = 0%) (Figure 4D).
Data on the stimulation length were available in 6
RCTs [18-22,24]. After meta-analysis, a significant effect
of metformin was observed on the stimulation length
(MD = -3.28, 95% CI -6.23 to 0.32, P = 0.030), withsignificant heterogeneity across the studies (P < 0.0001,
I2 = 96%) (Figure 5A).
After combining the data from all of the included
RCTs [18-24], significantly less gonadotropin units were
used under metformin (MD = -306.62, 95% CI -500.02
to -113.22, P = 0.002), with significant heterogeneity
across the studies (P < 0.00001, I2 = 96%) (Figure 5B).
The meta-analysis of all included RCTs [18-24] showed
a significant effect of metformin on serum E2 levels
(MD = -194.43, 95% CI -313.46 to -75.40, P = 0.001), with
significant heterogeneity across the studies (P < 0.00001,
I2 = 99.0%) (Figure 5C).Per-protocol analysis
Figures 6 and 7 show the primary and secondary end-
points analyzed according to the per-protocol principle.
Data on the live birth rate were available in 2 RCTs
[21,24]. Metformin increased significantly the live birth
rate (OR = 1.94, 95% CI 1.10 to 3.44, P = 0.020), without
significant heterogeneity across the studies (P = 0.230,
I2 = 30%) (Figure 6A).
Based on meta-analysis of all included RCTs [18-24],
metformin significantly increased the pregnancy rate
(OR = 2.20, 95% CI 1.47 to 3.31, P = 0.0001), without
Figure 4 Meta-analysis of clinical secondary endpoints performed using ITT principles. Multiple pregnancy (A), miscarriage (B), cycle
cancellation (C) and OHSS (D) rates.
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Figure 5 Meta-analysis of stimulation secondary endpoints performed using ITT principles. Stimulation lenght (A), gonadotropin units (B)
and serum E2 levels (C).
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Figure 6 Meta-analysis of primary endpoints performed using per-protocol principle. Live-birth (A) and pregnancy (B) rates.
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I2 = 0%) (Figure 6B).
After meta-analysis of 6 RCTs [18-22,24] no significant
effect of metformin was observed on the stimulation
length (MD= -2.15, 95% CI -5.01 to 0.71, P = 0.140), with
significant heterogeneity across the studies (P < 0.0001,
I2 = 95%) (Figure 7A).
After combining the data from all of the included RCTs
[18-24], significantly lower gonadotropin doses were ob-
served under metformin (MD= -282.89, 95% CI -473.23
to -92.55, P = 0.040), with significant heterogeneity across
the studies (P < 0.00001, I2 = 96.0%; Figure 7B).
The meta-analysis of all included RCTs [18-24]
showed a significant effect of metformin on serum E2
levels (MD = -190.59, 95% CI -314.52 to -66.67, P =
0.003), with significant heterogeneity across the studies
(P < 0.00001, I2 = 99.0%) (Figure 7C).
No significant effect of metformin on other secondary
endpoints analyzed was detected (data not shown).
Discussion
The present systematic review and meta-analysis dem-
onstrated that metformin improves the pregnancy rate
of more than two-fold with the NNT of 5.7 benefits
without heterogeneity among studies [18-24]. Thisbeneficial effect seems to translate into a significantly
better rate of live births. In fact, metformin administra-
tion increased significantly also the live birth rate of
about two-fold. Moreover, only two RCTs [21,24] evalu-
ated the live birth rate as study endpoint on a total of
298 and 363 cycles performed under metformin or no
treatment/placebo, respectively.
The benefit of metformin treatment in improving live
birth and pregnancy rates was confirmed also after data
synthesis performed according to per protocol principle.
Although this kind of analysis is generally used for
safety-related outcomes, we would explore the specific
effect of metformin on gonadotropin stimulation, ex-
cluding the patients who had a pregnancy under metfor-
min during the pre-treatment phase [27].
Current data showed a reduced rate of cancelled cycles
in PCOS patients who received metformin. In particular,
less cycles resulted cancelled both for excessive and poor
response under metformin. Of note, in 3 RCTs [21-23]
was demonstrated a higher proportion of PCOS patients
who achieved monofollicular cycles under metformin,
and mono-ovulation should be considered the best result
for treating anovulatory infertility.
The reduction in cancellation rate is very important
from a clinical point of view, and could be crucial for
Figure 7 Meta-analysis of secondary endpoints performed using per-protocol principle. Stimulation lenght (A), gonadotropin doses (B)
and serum E2 levels (C).
Palomba et al. Reproductive Biology and Endocrinology 2014, 12:3 Page 12 of 15
http://www.rbej.com/content/12/1/3
Palomba et al. Reproductive Biology and Endocrinology 2014, 12:3 Page 13 of 15
http://www.rbej.com/content/12/1/3the reproductive benefit of metformin. However, at the
moment, it is not possible to define the real impact of
the reduction in cancellation rate on the increased preg-
nancy/live birth rate. To this regard, a specific data
synthesis of the noncancelled cycles would be useful.
Unfortunately that analysis was not possible for the lack
of this outcome in many papers. Thus, we can
hypothesize that the beneficial effect of metformin on
reproduction can be explained not only with the fewer
cancelled cycles, but also with a potential effect on oo-
cyte quality and/or endometrial competence that cannot
be formally excluded.
To this regard, human and animal studies [3-6,28-32]
suggested the effect of metformin on the ovary by im-
proving both the intra-ovarian hyperandrogenism and
the intra-ovarian insulin-resistance.
Regarding the endometrial receptivity, similarly to what
occurred in IVF cycles [8], the current meta-analysis
showed that serum E2 levels were lower in PCOS patients
who received metformin. This figure could affect the
endometrial receptivity. However, experimental data
[33,34] demonstrated a direct effect of metformin on the
endometrium of PCOS patients. Moreover, no effect on
the miscarriage rate was detected under metformin, con-
firming our previous meta-analysis on the lack of any ef-
fect of metformin on the risk of miscarriage in infertile
PCOS patients under treatment [35]. On the other hand, a
reduced risk of miscarriage and of implantation failure
under metformin therapy was recently observed in PCOS
patients undergoing IVF cycles [8].
Current data demonstrated no beneficial effect of met-
formin on OHSS risk in patients who received gonado-
tropins for ovulation induction, whereas only a trend
was found for multiple pregnancies. These findings can
be explained by the very low risk for and incidence of
OHSS and multiple pregnancy observed in many of the
included studies due to use of safe gonadotropin proto-
cols and strict criteria for ovulation triggering.
The main strengths of the current systematic review
and meta-analysis regard the use of strict inclusion and
exclusion criteria, the lack of heterogeneity in all pri-
mary reproductive outcomes assessed, and the absence
of further clinical trials or RCTs in progress or only de-
signed that make current data conclusive for the next
few years.
However, a definitive interpretation of the data and
general applicability of the findings to make clinical
recommendations seemed to be premature. In fact, the
present meta-analysis has several limitations not regard-
ing only the overall study quality (Figure 2).
First of all, it included a limited number of studies and
of subjects. In fact, after a careful bibliographic search,
only 7 RCTs were included in the final analysis, for an
overall population of about 300 subjects. The publicationbias was not tested in our analysis in consideration of
the low power due to small number of studies included.
In addition, many of the included studies had an open
design and lacked adequate power analysis.
Secondly, infertile PCOS populations with heteroge-
neous characteristics were studied. Only 5 out of 7 in-
cluded RCTs utilized conventional criteria for PCOS
diagnosis, no standardization or sub-analysis according
to phenotype was possible, and there was no distinction
between CC-resistant patients and CC responders. In
addition, factors such as insulin resistance and/or body
mass index (BMI) may have biased our results. Unfortu-
nately, no sub-analysis according to BMI was possible
since almost no included study selected its participants
for BMI and only few for insulin resistance. In addition,
several confounders related to other patient characteris-
tics, including previous parity, additional infertility diag-
nosis, duration of infertility, age, and so on may impact
our findings.
Finally, protocols for metformin administration were
heterogeneous. Specifically, metformin was given with a
daily dose of 1500 mg or 1700 mg. These differences in
metformin doses could again bias our findings, although
recent data [35] demonstrated the lack of significant
difference between metformin doses and treatment ef-
fectiveness even at lower dosages. On the other hand,
metformin was generally administrated as gonadotropin
pretreatment and coadministration, and only in 1 RCT
[23] it was given as pretreatment. Of note, no study ex-
plored the effect of metformin pretreatment alone.
Conclusions
The current systematic review with meta-analysis dem-
onstrated that metformin administration significantly
increases the live birth and pregnancy rates of about
two-fold, and reduces the cancellation rate of about 60%
in PCOS patients who receive gonadotropins for ovula-
tion induction.
This beneficial effect on reproduction can be ex-
plained with an effect on the reduced cancellation rate,
even if an effect on oocyte and endometrial quality can-
not be excluded.
In consideration of the suboptimal quality of the stud-
ies included, further well designed, blinded, placebo-
controlled, and adequately powered RCTs are need to
confirm current results. Unfortunately, no clinical trial
on this issue is currently underway.
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